According to the information provided, there is at least one clinical trial that supports the use of Polivy (generic name: polatuzumab vedotin) in the treatment of lymphoma. Polivy is an FDA-approved antibody-drug conjugate used for the treatment of certain types of lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

The clinical trial in question is the GO29365 study, a randomized, double-blind, active-controlled, multicenter, phase 3 trial. The study compared the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Polivy + BR) versus bendamustine and rituximab alone (BR) in patients with relapsed or refractory DLBCL. The results of the study demonstrated that patients treated with Polivy + BR had a significantly higher overall response rate (ORR) and complete response rate (CRR) compared to those treated with BR alone.

The GO29365 study was presented at the American Society of Hematology (ASH) Annual Meeting in December 2018 and published in The Lancet Oncology in February 2019.

Sources:

1. [Polivy Prescribing Information](https://www.drugs.com/pro/polivy.html)
2. [GO29365 Study Results](https://ash.confex.com/ash/2018/webprogram/Paper115633.html)
3. [Polatuzumab Vedotin Plus BR Versus BR Alone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30999-3/fulltext)
4. [Polatuzumab Vedotin in Lymphoma: Current Status and Future Directions](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173523/)
5. [Polivy (polatuzumab vedotin-piiq) for Injection, for Intravenous Use](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761158s000lbl.pdf)
6. [DrugPatentWatch.com - Polivy (polatuzumab vedotin)](https://www.drugpatentwatch.com/drugs/polivy)